Corbus Pharmaceuticals ( (CRBP) ) has shared an announcement.
Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company based in Norwood, Massachusetts. The company focuses on developing innovative treatments for cancer and obesity, with a diversified portfolio that includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment.
YTD Price Performance: -43.60%
Average Trading Volume: 265,325
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $82.7M
See more insights into CRBP stock on TipRanks’ Stock Analysis page.